Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001558370-22-000599
Filing Date
2022-01-28
Accepted
2022-01-28 17:25:58
Documents
16
Period of Report
2021-11-12
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A kala-20211112x8ka.htm   iXBRL 8-K/A 39628
2 EX-23.1 kala-20211112xex23d1.htm EX-23.1 3857
3 EX-99.2 kala-20211112xex99d2.htm EX-99.2 474564
4 EX-99.3 kala-20211112xex99d3.htm EX-99.3 392610
5 GRAPHIC kala-20211112xex99d2001.jpg GRAPHIC 6264
  Complete submission text file 0001558370-22-000599.txt   1101295

Data Files

Seq Description Document Type Size
6 EX-101.SCH kala-20211112.xsd EX-101.SCH 3150
7 EX-101.LAB kala-20211112_lab.xml EX-101.LAB 15926
8 EX-101.PRE kala-20211112_pre.xml EX-101.PRE 10061
10 EXTRACTED XBRL INSTANCE DOCUMENT kala-20211112x8ka_htm.xml XML 4920
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38150 | Film No.: 22570222
SIC: 2834 Pharmaceutical Preparations